Despite the clinical benefits of treating obesity and related complications, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are not yet covered by Medicare Part D, partly due to high drug costs. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.